Search results for

Counsel at Thyssenkrupp, Visteon, and a fintech and biotech company share their advice for communicating the value of IP to their C-suite

Managing IP will be hosting its annual awards in March 2020 in London and New York and June 2020 in Shanghai. Now in their 15th year, the Managing IP Awards recognise the top IP practitioners, firms and in-house counsel from around the world.

Protection of geographical indications (GIs) has attracted increasing attention from the governments of various countries, and GIs have become one of the key issues that led to the creation of an important component of bilateral and multilateral international trade agreements. According to the 1994 Agreement On Trade-related Aspects of Intellectual Property Rights (the TRIPS Agreement), GIs are defined as "indications which identify a good as originating in the territory of a member, or a region or locality in that territory, where a given quality, reputation or other characteristic of the good is essentially attributable to its geographical origin."

With the EU taking a tough line on proving genuine trademark use – and with further case law looming – brands say early-stage conversations are increasingly relevant

The long-awaited Trademarks Act 2019 (2019 Act) finally came into force in December 2019. The enactment of the 2019 act effectively repeals its predecessor – the Trade Marks Act 1976 (1976 act). Among its various developments, a notable addition is the criminalisation of the act of counterfeiting trademarks. Part XV of the 2019 act deals with criminal offences, which were not dealt with under the 1976 act. Prior to the enactment of the Trademarks Act 2019, the criminal offences and enforcement provisions lay within the ambit of the Trade Descriptions Act 2011 (2011 act). The 2019 act has consolidated such provisions to comprehensively cover criminal offences, enforcement and penalties within the act.

The TRIPS Agreement, to which the Philippines is a signatory, enables governments of member countries with no capacity to manufacture medicines to import/export cheaper pharmaceutical products via a compulsory licence. These are medicines for which they would otherwise have paid a higher price because of existing patents.

On December 25 2019, the Supreme Court promulgated amendments of Several Provisions on Civil Evidence Rules (amendments). The amendments, which will come into effect on May 1 2020, have attracted lots of attention from IP practitioners. The rules are expected to improve the accuracy and standardisation of evidence production procedures and balance the burden of proof between litigants. Below are some highlights of the amendments.

Novel decision outlines ambitious step that China’s supreme court is taking to make it more efficient to enforce patent rights

Counsel at Brandit, a dating app and Hitachi discuss how data mining can aid IP enforcement, the pitfalls of storing too much data and filing strategies

Generics and innovator pharma companies welcome December’s SPC decision from a UK court, saying it further clarifies an uncertain regulation, but believe it will introduce prosecution challenges